Multidisciplinary Approaches to the Management of Atopic Dermatitis - Episode 7
Navigating New Treatment Options for Pediatric Atopic Dermatitis Management
Published on:
Panelists discuss the role of newer agents, including biologics/monoclonal antibodies (dupilumab, tralokinumab, lebrikizumab) and Janus kinase (JAK) inhibitors (abrocitinib, baricitinib, upadacitinib), in the treatment of moderate to severe atopic dermatitis, emphasizing their effectiveness in improving outcomes for patients who do not have adequate control with conventional therapies.
Video content above is prompted by the following:
3. Where do you see the newer agents fitting into moderate to severe atopic dermatitis treatment?
a. Biologics/monoclonal antibodies: dupilumab, tralokinumab, lebrikizumab
b. JAK inhibitors: abrocitinib, baricitinib, upadacitinib
